

May 06, 2024

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Press Release – Grant of INVIMA approval

Attaching herewith a Press Release regarding grant of approval by Colombia's INVIMA for the Softgel Capsules division of the company at Puducherry. Request you to take the same on record.

Thanking You,

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G

General Counsel & Company Secretary

Membership No. A23989

Encl: A/a

CAPLIN POINT GETS COLOMBIA APPROVAL FOR SOFTGEL CAPSULES

Chennai, May 06, 2024: Caplin Point Laboratories Limited (BSE: CAPLL (524742), NSE: CAPLIPOINT) has received Colombia's INVIMA approval for its Softgel Capsules division at Puducherry. The site inspection of Unit-1 was completed on May 3rd and found compliant as per INVIMA's norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).

Commenting on the approval, Mr.C.C.Parthipan, Chairman, Caplin Point Laboratories Limited said "Expansion into larger markets of Latin America such as Colombia, is an important aspect of our future growth, and this approval, especially in the niche Softgel Capsules range will contribute well to the same."

The Unit currently caters to Emerging Markets of Latin America and Africa with a variety of dosage forms such as Tablets, Capsules, Softgel Capsules, Suppositories, Liquid Orals, Topicals and Injectables

About Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. Caplin Point is one of the few companies to show consistent high-quality growth in cashflows, Profitability and Revenues over the last 15 years.

Caplin Point has appeared on **Forbes "Asia's 200 Best Under a Billion"** list for an unprecedented 6th time in the last 10 years, and was awarded "The Emerging Company of 2018" and "Business Excellence Award for 2019" by Economic Times.

CAUTIONARY STATEMENT:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Caplin

Mr G Venkatram (General Counsel & Company Secretary)

Tel: +91 44 24968000

investor@caplinpoint.net

Churchgate Partners

Anvita Raghuram / Rajiv Pandya

Churchgate Partners

+91 22 6169 5988

caplinpoint@churchgatepartners.com

Registered Office

Caplin Point Laboratories Limited

3rd Floor, Ashvich Tower, No. 3, Developed

Plots Industrial Estate, Perungudi,

Chennai – 600 096, Tamil Nadu, INDIA.

Tel: +91 44 2496 8000

CIN: L24231TN1990PLC019053

ISIN: INE475E01026

NSE Code: CAPLIPOINT

BSE CODE: 524742

Website: www.caplinpoint.net